Open AccessOnce-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
Author(s) -
Michael Fried,
María Buti,
Gregory J. Dore,
Robert Flisiak,
Péter Ferenci,
Ira M. Jacobson,
Patrick Marcellin,
Michael P. Manns,
I V Nikitin,
Fred Poordad,
Morris Sherman,
Stefan Zeuzem,
Scott Jordan,
L. Gilles,
Oliver Lenz,
Monika Peeters,
Vanitha Sekar,
Goedele De Smedt,
Maria Beumont-Mauviel
Publication year - 2013
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/wfr0-7y45
Subject(s) - ribavirin , simeprevir , pegylated interferon , hepatitis c , genotype , virology , medicine , randomized controlled trial , pillar , hepatitis c virus , gastroenterology , biology , gene , genetics , virus , structural engineering , engineering